Navigation Links
Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission
Date:9/5/2007

Significant Difference in Primary Endpoint Could be Acceptable With Fewer

Patients Than Originally Planned

SEATTLE, Sept. 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC) (MTAX: CTIC) announced today that following discussions with the U.S. Food and Drug Administration (FDA) regarding its EXTEND (PIX301) trial for patients with aggressive non-Hodgkin's lymphoma (NHL) the Company has decided to conduct a full analysis of the trial instead of an interim analysis as previously planned. The decision was based in part on the Agency's guidance that a primary endpoint analysis of less than the initially-projected 320 eligible patients could be acceptable for New Drug Application (NDA) submission if it is able to demonstrate a statistically significant (p<=0.05) difference between treatment arms. In addition, the FDA agreed that randomized safety data from the RAPID (PIX203) study (CHOP-R vs. CPOP-R) could be used to support the EXTEND results in an NDA submission for pixantrone. Based on this guidance the Company currently anticipates completing enrollment in the EXTEND trial in the fourth quarter of this year with primary endpoint data and final results being reported in the first half of 2008. Pixantrone has received fast track status from the FDA for this indication.

"This was a very important outcome for CTI and the PIX301 trial timeline. If we achieve the primary endpoint of the study, even with fewer than 320 patients, we could submit our NDA" said James A. Bianco, M.D., President and CEO of CTI. "Going straight to a final analysis will allow us the potential to submit an NDA for pixantrone and receive approval in 2009. The inclusion of safety data from the rand
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Extended data analysis using DeCyder EDA
2. Detection of N-in-1 Experiments: Extending the Range of N Using the API 3000 LC/MS/MS System
3. Techware to extend broadband wireless network to Butler
4. UW gets $5M to extend entrepreneurship
5. Creativity, innovation extend to municipalities
6. NimbleGen extends research market reach
7. TomoTherapy extends reach to Germany
8. Third Wave says patent extends IP reach
9. `Single-sales factor extends tax treatment to tech, service firms
10. Alumni Association extends database help to university
11. UW-Madison working to extend wireless access to entire campus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , September 22, 2014 ... on a mixed note as the Dow Jones Industrial ... Composite closed at 4,579.79, down 0.30%. The S&P 500 ... trading session, six out of ten sectors finished on ... Index ended the day at 751.48, up 0.10%, with ...
(Date:9/22/2014)... 2014  Spherix Incorporated (SPEX) -- an intellectual property development ... today announced that the United States Patent & Trademark Office ... month of September that is part of a standard essential ... USRE45,121 , Application number: US 13/728,867 , ... 27, 2012 The listed inventors of the ...
(Date:9/21/2014)... Chemical Sciences play a significant role in meeting ... safe water, healthy food, and dependable medicine from ... educators, and scientists have a great role in ... for the national development, and to foster research ... emerging Sciences, accelerating with a tremendous speed to ...
(Date:9/20/2014)... 20, 2014 MediVet America ... a groundbreaking surgery at the specialized Wolvega Horse Clinic. ... digital flexor tendon was ruptured 90% and her deep ... is a death sentence for a horse. , The ... cell treatments . This revolutionary regenerative option for ...
Breaking Biology Technology:Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3Chemistry for Global Development during the Open Access Week 2Chemistry for Global Development during the Open Access Week 3World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3
... 24 Huntsman Advanced Materials, a division ... announced it was awarded the JEC Award for innovative ... Huntsman received the award for the innovative use of ... with its US-based customer GrafTech International.Andre Genton, President of ...
... S.A. and,Solvay Pharmaceuticals Marketing and Licensing AG (subsidiary ... partnership agreement for the,promotion and distribution of Stallergenes ... of Independent States (CIS). , ... and a strong demand on the,part of the ...
... than 80% of Nearly 4,000 Participants Attend InformexUSA ... Chemical IndustryPRINCETON, N.J., March 24 In a ... the United States -- InformexUSA -- visitors affiliated ... said they remain on the look-out for new ...
Cached Biology Technology:Huntsman Innovation Wins Top Award at Paris JEC Show 2Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS* 2Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS* 3Informex Survey Shows Innovation Remains a Priority for 2009 and Beyond 2Informex Survey Shows Innovation Remains a Priority for 2009 and Beyond 3
(Date:9/21/2014)... newborn immune T cells may have the ability to ... new study led by King,s College London. Although their ... babies may still be able to mount a strong ... Nature Medicine . , Our immune system is ... including neutrophils which play an important role in the ...
(Date:9/19/2014)... unveiled today by researchers from several Harvard University ... both experienced and aspiring researchers with the intellectual ... robots made from soft, flexible materials. , With ... and other advances in manufacturing technology, soft robotics ... principles drawn from conventional rigid robot design, but ...
(Date:9/19/2014)... species which over thousands of years has adapted to the ... that makes the cold dangerous for you. , This is ... and the cold provoking substance, called nonylphenol, comes from the ... suspected of being a endocrine disruptor, but when entering the ... ability to protect the cells in its body from cold ...
Breaking Biology News(10 mins):Immune system of newborn babies is stronger than previously thought 2Soft robotics 'toolkit' features everything a robot-maker needs 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... to act cancerous, surviving, growing and reproducing out of ... characteristics to stop growing or to die. In breast ... sometimes promoting tumors and sometimes suppressing them. A ... the journal Oncogene details how tumors may ...
... of Texas at Austin researchers have demonstrated a new ... the heart and limbs a research advancement that ... disease, the leading cause of death in the Western ... of Engineering Assistant Professor Aaron Baker could allow doctors ...
... available in German . The Deutsche ... four new Research Units. This decision was taken by the ... of the research consortia is to offer researchers the opportunity ... and to establish innovative research directions. As with ...
Cached Biology News:Study details on-off switch that promotes or suppresses breast cancer 2New ability to regrow blood vessels holds promise for treatment of heart disease 2New ability to regrow blood vessels holds promise for treatment of heart disease 3DFG to establish 4 new research units 2DFG to establish 4 new research units 3
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Tropomyosin 4 [Tm4]...
...
Biology Products: